All In Biotech

Drug Trial Radar · NCT00141102

Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events

Last checked: Nov 19, 2026Latest source record: Mar 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 4,484 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,484

Actual

Start

Oct 2005

Primary completion

May 2009

Study completion May 2009

Sponsor

Sponsor type
Industry
First posted
Sep 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.

Conditions

  • Osteoarthritis
  • Arthritis, Rheumatoid

Interventions

  • CelecoxibDrug

    Participants are assigned to one of two groups in parallel for the duration of the study

  • Diclofenac + OmeprazoleDrug

    Participants are assigned to one of two groups in parallel for the duration of the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)Time frame: 6 month treatment duration

Locations

194 sites in 32 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Genk, Belgium

  • Pfizer Investigational Site

    Ghent, Belgium

  • Pfizer Investigational Site

    Hasselt, Belgium

  • Pfizer Investigational Site

    Liège, Belgium

  • Pfizer Investigational Site

    Goiânia, Goiás, Brazil

  • Pfizer Investigational Site

    Goiânia, Goiás, Brazil

  • Pfizer Investigational Site

    Curitiba, Paraná, Brazil

  • Pfizer Investigational Site

    Curitiba, Paraná, Brazil

  • Pfizer Investigational Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Pfizer Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Pfizer Investigational Site

    São Paulo, São Paulo, Brazil

  • Pfizer Investigational Site

    São Paulo, São Paulo, Brazil

  • Pfizer Investigational Site

    São Paulo, São Paulo, Brazil

  • Pfizer Investigational Site

    Winnipeg, Manitoba, Canada

  • Pfizer Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • Pfizer Investigational Site

    Hamilton, Ontario, Canada

  • Pfizer Investigational Site

    Newmarket, Ontario, Canada

  • Pfizer Investigational Site

    Windsor, Ontario, Canada

  • Pfizer Investigational Site

    Pointe-Claire, Quebec, Canada

  • Pfizer Investigational Site

    Sherbrooke, Quebec, Canada

  • Pfizer Investigational Site

    Ste Foy, Quebec, Canada

  • Pfizer Investigational Site

    Beijing, China

  • Pfizer Investigational Site

    Beijing, China

  • Pfizer Investigational Site

    Beijing, China

  • Pfizer Investigational Site

    Beijing, China

  • Pfizer Investigational Site

    Shanghai, China

  • Pfizer Investigational Site

    Shanghai, China

  • Pfizer Investigational Site

    Tianjin, China

  • Pfizer Investigational Site

    Tianjin, China

  • Pfizer Investigational Site

    Guangzhou, Guangdong, China

  • Pfizer Investigational Site

    Nanjing, Jiangsu, China

  • Pfizer Investigational Site

    Chengdu, Sichuan, China

  • Pfizer Investigational Site

    Medellín, Antioquia, Colombia

  • Pfizer Investigational Site

    Barranquilla, Atlántico, Colombia

  • Pfizer Investigational Site

    Barranquilla, Atlántico, Colombia

  • Pfizer Investigational Site

    Bogota, Cundinamarca, Colombia

  • Pfizer Investigational Site

    Floridablanca, Santander Department, Colombia

  • Pfizer Investigational Site

    Cartago, Costa Rica

  • Pfizer Investigational Site

    Heredia, Costa Rica

  • Pfizer Investigational Site

    San José, Costa Rica

Showing 40 of 194 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.